ReviewAnnals of translational medicine2022

Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.

Linhui Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.